Efficacy of a synthetic pentasaccharide, a pure factor Xa inhibitor, as an antithrombotic agent--a pilot study in the setting of coronary angioplasty.

@article{Vuillemenot1999EfficacyOA,
  title={Efficacy of a synthetic pentasaccharide, a pure factor Xa inhibitor, as an antithrombotic agent--a pilot study in the setting of coronary angioplasty.},
  author={A Vuillemenot and François Schiele and Nicolas F. Meneveau and Sylvette Claudel and François Donat and Sylvie Fontecave and Roger Cariou and Michel Meyer Samama and Jean Pierre Bassand},
  journal={Thrombosis and haemostasis},
  year={1999},
  volume={81 2},
  pages={214-20}
}
AIM OF THE STUDY To assess the antithrombotic properties of SR90107/ORG31540. a sulfated pentasaccharide, which enhances specifically antithrombin III mediated inactivation of factor-Xa, in a clinical setting known to promote arterial thrombosis, i.e. coronary angioplasty. METHODS AND RESULTS Percutaneous transluminal coronary angioplasty (PTCA) was carried out with conventional balloons with a single 5 min intravenous infusion of 12 mg pentasaccharide, and 500 mg intravenous aspirin. Heparin… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

Similar Papers

Loading similar papers…